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antiresorptive agents against each other didn’t evidence a statistically signiﬁcant 
difference. ConClusions: The results of this MTC can suggest that Risedronate, 
compared to placebo, is expected to provide the highest rate of reduction in NVF in 
women affected by postmenopausal OP. However, the mixed treatment comparisons 
among alendronate, risedronate, ibandronate, zolendronate and denosumab did not 
evidence a statistically significant difference.
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objeCtives: The Start Excursion Balance test (SEBT) is commonly used to assess 
the dynamic stability of the trunk and lower extremities in which eight times three 
(8x3) measurements are made, this means a total of 48 measurements on the two 
sides. The aim of this research is to create a simpler and faster balance test and 
to compare this with other validated balance tests. Methods: The study was 
implemented in August 2014 at the University of Pécs Faculty of Health Sciences 
Zalaegerszeg Training Centre in which 11 adult and 30 youth basketball players play-
ers were involved (mean age: 14.9 year, mean height: 179.9cm). The Dynamic Lateral 
Balance Test (DLBT) is based on a newly developed methodology and use a simple 
calliper to measure the values. To assess the strength of the relationship between 
the specific tests ( SEBT, Flamenco Test and DLBT) Pearson correlation coefficients 
were computed. Statistical significance was established at the α -level of 0.05 for all 
analyses, and IBM SPSS, Inc., 20.0v was used. Results: We found moderate cor-
relation between the values of the DLBT and the body height(p< 0.001), therefore we 
expressed the values correlated with body height(DLBT / body height x 100). There 
wasa moderate negative correlate between the values of the Flamenco Test and 
the DLBT test (left side: r = -0.424, p = 0.006; right side: r = -0.432, p = 0.005). There 
was a moderate positive correlation between the DLBT and the SEBT regarding 
some directions (p < 0.05), for example: right DLTB – right posteromedial: r = 0.480, 
p = 0.002; left DLBT – left posteromedial: r = 0.491, p = 0.002. ConClusions: The 
present pilot study confirmed the correlation between the newly developed DLBT 
and other validated tests; consequently this new test can become a fast, simple and 
informative solution for testing the dynamic balance.
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objeCtives: Psoriasis and Psoriatic Arthritis (PsA) are chronic, inflammatory, 
autoimmune diseases that negatively impact on health-related quality of life. 
The aim of this study was to analyze the healthcare profile and the overall cost 
of patients with Psoriasis/PsA in the real clinical practice. Methods: From 
ARNO Observatory database we carried out a record linkage analysis of disease 
exemptions, drug prescriptions and specialist services on 2.988.195 subjects, with 
available, complete and good quality data. Patients with Psoriasis/PsA were col-
lected from 01/01/2009 to 31/12/2011 (accrual period) and followed up to 2 years, 
to analyze specific treatments (DMARDs, biological, topical), therapy switches, 
community and hospital cares and their expenditure (mean/patient). Results: 
Of 2.988.195 subjects, 6.030 met two or more inclusion criteria (53% men, mean 
age 54,5±14,6 years). During the 2-year follow-up non-biological and biological 
drugs were prescribed respectively to 2.738 (45%) and to 902 (15%) patients. 591 
took both: 390 (66%) started DMARDs then switched to biological treatments in 7±6 
months on average. 2.783 (46%) patients received “other drugs”, mostly NSAIDs, 
Corticosteroids (systemic and dermatological use), Penicillins and Quinolone anti-
bacterials. 950 patients (16%) were discharged from ordinary and daily hospitaliza-
tions mainly for skin, connective tissue and cardiovascular (CVD) diseases. CVD 
and Neoplasia (8195€ /patient/2-year follow-up) were between the most expensive 
causes of ordinary admissions. Psychiatric disorders caused the longest stay in-
hospital (33,5 mean days/patient). 51,5% of patients received specialist healthcare 
services (blood count and liver enzymes). Patients treated with biological drugs 
were more expensive than those treated with DMARDs and topical therapies, for 
pharmaceutical, in-hospital and specialist cares (7.978€ /patient/year of follow-
up). ConClusions: This assessment of healthcare profiles of patients with 
Psoriasis/PsA in the real in-hospital and community Italian settings provided 
evidence that patients treated with biological therapies are those with a more 
compromised health that induces high costs on all aspects of their care.
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objeCtives: The epidemiology and treatment patterns of osteoporosis are poorly 
understood in Portugal. Available evidence suggests that many post-menopausal 
(PM) women with osteoporosis are not pharmacologically treated for this condi-
tion (i.e. under-treatment). Furthermore, high levels for treatment discontinua-
tion (i.e. non-persistence) are still reported in the clinical practice. We aimed to 
describe the treatment patterns of PM osteoporosis and to understand reasons for 
under-treatment and non-persistence in Portugal. Methods: This is an observa-
tional, cross-sectional study, nested in a patient registry database developed by the 
Portuguese Society of Rheumatology, and conducted during 2014. Complementary 
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objeCtives: For patients with polyarticular juvenile idiopathic arthritis (pJIA), a 
published indirect comparison1 demonstrated that abatacept, adalimumab and 
etanercept are similarly efficacious, as measured by preventing disease flare after 
response to treatment. The objective of this study was to indirectly assess the effi-
cacy and safety of abatacept, adalimumab and etanercept compared to tocilizumab 
in patients with pJIA. Methods: There have been no head-to-head trials comparing 
biological disease modifying anti-rheumatic drugs (bDMARDs) in patients with pJIA. 
A published systematic review and indirect comparison did not include tocilizumab. 
Therefore, we conducted an indirect comparison, using the Bucher method, to esti-
mate the efficacy of tocilizumab compared with the other bDMARDs. The definition 
of pJIA and baseline characteristics of patients in the tocilizumab trial were similar 
to the trials included in the published study. We also compared the incidence of 
serious adverse events (SAEs) during the double-blind phase of the trials for each 
bDMARD versus placebo using Fisher’s exact test. Results: The relative risk of 
preventing disease flare after response to treatment for abatacept, adalimumab and 
etanercept versus tocilizumab in patients with pJIA was 0.71 (95% CI: 0.35-1.43), 1.10 
(95% CI: 0.64-1.91) and 0.65 (95% CI: 0.30-1.43), respectively. The incidence of SAEs 
for each bDMARD was not significantly different when compared to placebo, with 
Fisher’s exact test p-value as 0.50, 0.49, 0.24 and 1.00, for abatacept, adalimumab, 
etanercept, and tocilizumab, respectively. ConClusions: We conclude that abata-
cept, adalimumab, etanercept and tocilizumab have comparable efficacy in pJIA 
in preventing disease flare after response to treatment. The incidence of SAEs for 
each bDMARD was not statistically significantly different from that of placebo, 
and therefore was likely to be generally comparable between the bDMARDs. As the 
efficacy and safety of these bDMARDS are comparable, cost-minimisation analysis 
is an appropriate method for economic evaluation of these treatments. 1 Otten MH, 
et al. AnnRheumDis 2013;72:1806–1812
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objeCtives: Rheumatoid arthritis (RA) is a chronic disease characterized by 
inflammation of the synovial tissue leading to joint destruction. The introduction 
of biologic agents dramatically changed the prognosis of RA, especially when admin-
istered in early RA (ERA). At now there are 8 different biologic agents approved 
for the therapy of ERA. The aim of this Bayesian metanalysis is to compare and 
rank biologics indicated for ERA. Methods: A literature search was performed 
to identify articles reporting data from RCTs on the use of biologic approved for 
ERA. MTC results are reported as the relative risk of response (RR), intended as 
the capacity of inducing an ACR20, ACR50 and ACR70 response for each biologic 
associated to MTX compared with MTX. Results: A total of 10 scientific papers 
were identified. Studies differed for length of followup and consequently only data 
at 12 weeks were taken into account. All biologic agents, associated to MTX, proved 
to be more efficacious in inducing an ACR20, ACR50 and ACR70 response respect to 
MTX. When comparing results obtained by different drugs, Etanercept proved to be 
the biologic agent that represents the best choice for obtaining ACR20 and ACR50 
response with a probability of 62,95% and 37,1% respectively, while Adalimumab 
represents the best choice for inducing ACR70 response with a probability of 
33,28%. ConClusions: In our MTC on RCTs on the use of biologic agents used 
in ERA, we identified Adalimumab as the more probably best choice in obtaining 
the result of ACR70 response and for such reason this drug should be considered 
as a first line therapy in patients affected by ERA. Etanercept proved to be the more 
probably best choice in obtaining ACR50 and ACR20 response, and for such reason 
it should be considered as the second line choice in patients affected by early RA.
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objeCtives: Osteoportic non Vertebral fractures (NVF) resulted the more frequent 
kind of fracture in large population studies, with a severe incidence on annual 
costs for the health system and an increased risk of death for fractured patients. 
The burden of fracture is expected to increase with an ageing population. Data 
from head to head RCT focused on reduction of incidence of non vertebral frac-
ture among available antiresorptive agents are not availabe. This MTC aims to 
compare alendronate, risedronate, ibandronate, zolendronate and denosumab on 
completion of preventing osteoporosis NVF in a Bayesian metaanalysis assessing 
indirect comparisons. Methods: A systematic research for RCT involving alen-
dronate, risedronate, ibandronate, zolendronate and denosumab was conducted 
using databases (CENTRAL, CINAHL,Embase, HMIC, MEDLINE and PsycINFO). MTC 
results are reported as the relative risk of response (RR), intended as the capacity 
of reducing NVF for each antiresorptive agent compared with placebo. Results: 
Nine RCTs were identiﬁed. Three trials compared Alendronate versus placebo, 2 
trials compared Risedronate vs placebo, 2 trials Zolendronate vs placebo, and one 
trial for ibandronate and denosumab. Risedronate had the highest probability (72%) 
of being the most effective treatment, followed by Zolendronate (22%), Denosumab 
(4,60%) and then alendronate (1%) and ibandronate (0.10%). Comparisons of any 
